Preclinical and first-in-human-brain-cancer applications of [¹⁸F]poly-(ADP-ribose) polymerase inhibitor PET/MR

AUTHORS: Robert J Young MD^{1,8}*[†], Paula Demétrio De Souza França MD^{1,2}[†], Giacomo Pirovano DPhil¹, Anna F Piotrowski MD^{3,8}, Philip J Nicklin¹, Christopher C Riedl MD PhD¹, Jazmin Schwartz PhD^{4,10,11}, Tejus A Bale MD PhD^{5,8}, Patrick L Donabedian¹, Susanne Kossatz¹, Eva M Burnazi¹, Sheryl Roberts PhD¹, Serge K Lyashchenko PharmD¹, Alexandra M Miller MD PhD^{3,8}, Nelson S. Moss MD^{6,8}, Megan Fiasconaro⁷, Zhigang Zhang PhD⁷, Audrey Mauguen PhD⁷, Thomas Reiner PhD^{1,9,10}[‡], Mark P Dunphy MD¹*[‡]

† RJY and PDSF contributed equally as co-first authors

‡ TR and MPD contributed equally as co-senior authors

AFFILIATIONS:

¹ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
² Department of Otorhinolaryngology and Head and Neck Surgery, Federal University of São
Paulo, SP, Brazil.

³ Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York
⁴ Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York

⁵ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
⁶ Department of Neurosurgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer
Center, New York, New York

⁷ Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York

⁸ The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York

9 Weill Cornell Medical College, New York, NY, USA

¹⁰ Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

¹¹ Department of Radiology, Weill Cornell Medical College, New York, NY, USA.

* Corresponding authors:

Robert J Young, MD

Neuroradiology Service, Department of Radiology

Memorial Sloan Kettering Cancer Center

1275 York Avenue

New York, New York 10065

Mark P Dunphy, MD Molecular and Imaging Therapy Services Department of Radiology Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, New York 10065 SUPPLEMENTARY MATERIAL:

Lesion	Diagnosis	Volume	SUV 60	SUV 120	Ratio SUV 60	Ratio SUV 120	DCE	DCE	Tumor ratio
		(cm3)	mean	mean	mean	mean	rKtrans	rVP	CCA
-	Not Tumor	129.9	0.31	0.24	0.52	0.63	1.15	1.41	0.37
7	Tumor	38.4	1.23	0.84	2.02	2.33	5	3.37	0.49
З	Not Tumor	48.1	0.48	0.38	0.79	1.06	2.5	1.57	0.39
4	Not Tumor	22.9	0.42	0.31	0.69	0.86	1.92	1.41	0.32
5	Not Tumor	112.9	0.75	0.66	0.75	1.05	2.8	1.9	0.53
9	Tumor	73.8	1.11	0.8	1.98	1.86	9.93	8.03	0.67
٢	Tumor	57.9	1.16	0.71	1.78	1.51	7.2	4.28	0.79
SUV60	= standardized	d uptake val	ue 60 min	after inject	ion				

SUV120 = standardized uptake value 120 min after injection

.

DCE = dynamic contrast enhanced T1 perfusion

rKtrans = ratio transfer coefficient constant lesion/normal (measure of leakiness)

VP = ratio plasma volume lesion/normal (measure of perfusion)

Tumor ratio = tumor / (tumor + necrosis)

CCA = contrast clearance analysis

Supplementary Table 1. Lesion measurements

Supplementary table 2. PARP1 expression (IHC)

Tissue Characteristic	Renal Carcinoma Lesion #6	GBM Lesion #7	Melanoma Lesion #2	Not Cancer Lesion #5	p-value ²
	$n = 12^{1}$	$n = 18^{1}$	$n = 37^{1}$	$n = 25^{1}$	
PARP1 expression	10(7,10)	14 (11 16)	7(2, 14)	2(1,5)	<0.001
(IHC)	10 (7, 10)	14 (11, 10)	/ (3, 14)	5(1, 5)	~0.001

¹Statistics presented: median (IQR)

²Statistical tests performed: Kruskal-Wallis test

Supplementary table 3. Data from the blocking experiment, showing that PARPi-FL specific uptake can be blocked by saturating the PARP1 enzyme with excess of PARP inhibitor.

Chanastanistia*	Signal < 3 Signal ≥ 3		p-value ²	
Characteristic	$n = 2251^{1}$ $n = 1453^{1}$			
Blocking			< 0.001	
Blocked	1136 (50%)	223 (15%)		
Unblocked	1115 (50%)	1230 (85%)		

¹ Statistics presented: n (%)

² Statistical tests performed: chi-square test of independence

*Dichotomization at \geq 3 vs < 3, analyzed using chi-square test



Supplementary Fig. 1. Metabolic stability and blood half-life of [¹⁸F]PARPi in patients with brain cancer. In total, blood samples from 3 patients were analyzed. (A) HPLC chromatogram of [¹⁸F]PARPi in human blood serum of a patient #2 at various time points post injection (1 min, 5 min and 30 min). (B) Weighted blood half-life of [¹⁸F]PARPi across all available patients (2-phase decay, no constraints, n = 3 patients). (C) Percentage of [¹⁸F]PARPi and its metabolites at various time points after injection (n = 3 patients).



Supplementary Fig. 2. Lesion 2 and lesion 3 on patient 2 scanned with [¹⁸**F**]**PARPi and** [¹⁸**F**]**FDG** Patient number 2, harbored 3 metastatic melanoma lesions treated with stereotactic radiosurgery around 10 months prior to imaging. (A) Lesion 2, on the left frontal lobe. This lesion presented with minimal perfusion and it was not seen on [¹⁸F]FDG scan. Imaging with [¹⁸F]PARPi demonstrated clear uptake. This lesion was surgically resected and histologically proven to be a viable metastatic melanoma. (B) Lesion number 3, right parietal lobe. This lesion also presented with minimal perfusion and it was not seen on [¹⁸F]FDG scan. However, imaging with [¹⁸F]PARPi demonstrated no uptake. This lesion was not surgically resected but was followed with imaging. This lesion was classified as treatment-related changes: determined by clinical and imaging follow

up based on the Response Assessment in Neuro-Oncology (RANO) criteria for primary brain cancers and the RANO brain metastasis (RANO-BM) criteria for secondary brain cancers.